Preoperative Ketorolac for Kidney Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Kidney Cancer+1 MorePreoperative Ketorolac - Drug
Eligibility
18 - 80
All Sexes
What conditions do you have?
Select

Study Summary

This study is evaluating whether a drug called ketorolac may help reduce the risk of cancer spreading after surgery.

Eligible Conditions
  • Kidney Cancer
  • Non-small Cell Lung Cancer

Treatment Effectiveness

Study Objectives

5 Primary · 11 Secondary · Reporting Duration: Baseline, Day 1, Day 3 (if admitted to hospital), Day 7, Day 28

Day 28
Change in Flow Cytometry
Change in Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Levels
Change in Interferon (INF)-gamma Levels
Change in Interleukin-1 alpha (IL-1alpha) Levels
Change in Interleukin-10 (IL-10) Levels
Change in Interleukin-12p70 (IL-12p70) Levels
Change in Interleukin-1beta (IL-1β) Levels
Change in Interleukin-2 (IL-2) Levels
Change in Interleukin-6 (IL-6) Levels
Change in Interleukin-8 (IL-8) Levels
Change in Monocyte Chemotactic and Activating Factor (MCAF) Levels
Change in Single Cell RNA Sequencing
Change in T-Cell Receptor (TCR) Sequencing
Change in Transcriptome Analysis
Change in Tumor Necrosis Factor-alpha (TNF-alpha) Levels
Day 7
Incidence of Blood Transfusion Among Ketorolac Group
Incidence of Clinically Significant Hematoma Development Among Ketorolac Group
Incidence of Postoperative Morbidity Rate Among Ketorolac Group
Incidence of Postoperative Renal Failure Among Ketorolac Group
Hemorrhage

Trial Safety

Trial Design

2 Treatment Groups

Control Group
1 of 2
Preoperative Ketorolac
1 of 2

Active Control

Experimental Treatment

76 Total Participants · 2 Treatment Groups

Primary Treatment: Preoperative Ketorolac · No Placebo Group · Phase < 1

Preoperative Ketorolac
Drug
Experimental Group · 1 Intervention: Preoperative Ketorolac · Intervention Types: Drug
Control GroupNoIntervention Group · 1 Intervention: Control Group · Intervention Types:

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, day 1, day 3 (if admitted to hospital), day 7, day 28

Who is running the clinical trial?

Emory UniversityLead Sponsor
1,509 Previous Clinical Trials
2,706,093 Total Patients Enrolled
Viraj Master, MD, PhDPrincipal Investigator - Emory University
Emory Saint Joseph's, Emory University Hospital, Emory University Hospital Midtown, Grady Memorial Hospital
University Of Chicago (Medical School)
University Ca Sf School Of Medicine (Residency)
1 Previous Clinical Trials
55 Total Patients Enrolled
Onkar Khullar, MDPrincipal InvestigatorEmory University

Eligibility Criteria

Age 18 - 80 · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: